Azintuxizumab vedotin

Modify Date: 2024-04-07 17:32:24

Azintuxizumab vedotin structure	Common Name	Azintuxizumab vedotin
	CAS Number	1826819-58-2	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Azintuxizumab vedotin

Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells[1].

Name	Azintuxizumab vedotin

Description	Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells[1].
Related Catalog	Research Areas >> Cancer
Target	CD2 subset 1[1]
In Vitro	Azintuxizumab vedotin (ABBV-838) 是一种 ADC，由人源化重组免疫球蛋白 G1κ 组成，针对 CD2 subset 1 (CS1，也称为 SLAMF7) 的独特表位，通过缬氨酸-瓜氨酸连接子与细胞毒性单甲基 auristatin E (MMAE) 结合[1]。 Azintuxizumab vedotin 对表达 CS1 的癌细胞显示出强大的细胞毒活性[1]。
In Vivo	Azintuxizumab vedotin (ABBV-838) 在使用人骨髓瘤异种移植的小鼠模型中显示单药抗肿瘤活性[1]。
References	[1]. Vij R, et al. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 May 15;26(10):2308-2317.

No Any Chemical & Physical Properties